Bod Science Limited (ASX: BOD) has established a loan facility with Radium Capital, a Research and Development finance provider, that will advance $437,598.00 to Bod representing the expected R&D tax incentive for H1 FY23, based on Bod's domestic R&D spend.
The loan is secured by a security agreement over the FY23 R&D tax rebate from the ATO and is repayable by 31st December 2023.
Bod Science is focused on researching and developing Cannabis related medicines with therapeutic indications for patients and consumers.